Nkarta Inc
NKTX2.020USD
+0.100+5.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
143.47MMarket Cap
LossP/E TTM
More Details of Nkarta Inc Company
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Nkarta Inc Info
Ticker SymbolNKTX
Company nameNkarta Inc
IPO dateJul 10, 2020
CEOHastings (Paul J)
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 10
Address1150 Veterans Boulevard
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone19254071049
Websitehttps://www.nkartatx.com/
Ticker SymbolNKTX
IPO dateJul 10, 2020
CEOHastings (Paul J)
Company Executives of Nkarta Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
175.30K
+67954.00%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
70.00K
+70000.00%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
175.30K
+67954.00%
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
70.00K
+70000.00%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
New Enterprise Associates (NEA)
5.02%
Samsara BioCapital, LLC
4.94%
SR One Capital Management, LP
4.69%
Other
60.20%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
15.21%
Tang Capital Management, LLC
9.93%
New Enterprise Associates (NEA)
5.02%
Samsara BioCapital, LLC
4.94%
SR One Capital Management, LP
4.69%
Other
60.20%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.89%
Hedge Fund
21.68%
Investment Advisor
15.39%
Investment Advisor/Hedge Fund
12.76%
Research Firm
2.00%
Individual Investor
1.12%
Family Office
0.09%
Bank and Trust
0.07%
Pension Fund
0.02%
Other
12.97%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
272
60.95M
85.81%
-23.37M
2025Q3
267
61.18M
86.14%
-27.32M
2025Q2
285
69.55M
98.01%
-21.71M
2025Q1
300
69.02M
97.27%
-22.80M
2024Q4
316
69.51M
100.26%
-10.53M
2024Q3
335
73.98M
106.61%
-9.96M
2024Q2
333
73.31M
105.81%
-2.74M
2024Q1
329
70.79M
102.89%
+13.14M
2023Q4
312
47.25M
96.07%
-11.76M
2023Q3
310
42.86M
87.43%
-15.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.81M
15.21%
--
--
Sep 30, 2025
Tang Capital Management, LLC
7.06M
9.93%
--
--
Sep 30, 2025
New Enterprise Associates (NEA)
3.57M
5.02%
--
--
Sep 30, 2025
Samsara BioCapital, LLC
3.51M
4.94%
-260.37K
-6.91%
Nov 20, 2025
SR One Capital Management, LP
3.33M
4.69%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.21M
4.52%
-443.45K
-12.13%
Sep 30, 2025
Citadel Advisors LLC
2.90M
4.08%
-398.07K
-12.07%
Sep 30, 2025
EQT Life Sciences
2.84M
3.99%
--
--
Feb 12, 2025
The Vanguard Group, Inc.
2.49M
3.51%
-62.56K
-2.45%
Sep 30, 2025
Alyeska Investment Group, L.P.
2.08M
2.94%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Invesco Raymond James SB-1 Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
